保健品龙头企业汤臣倍健近期启动了人工智能产业投资布局。自2026年4月以来，该公司合计投入约4.5亿元参与多家AI领域企业的融资，涉及DeepSeek、月之暗面、阶跃星辰等公司，并扩展到芯片领域。[1]
汤臣倍健通过多种渠道实现这一布局。公司出资1.3亿元通过砺思资本LP身份间接持有DeepSeek 0.04%的股权，该轮融资中DeepSeek的估值落在3250亿至3509亿元区间。[1]在月之暗面的投资中，汤臣倍健合计投入1500万美元参与融资，持有0.12%股权。[1]公司创始人梁允超的岳母孙晋瑜间接持有月之暗面股权，这一关联人脉关系为投资提供了渠道。[1]
支撑这一系列投资的是汤臣倍健充裕的财务状况。截至2025年末，公司货币资金达24.49亿元，资产负债率仅为19.95%，为其实施投资战略提供了资金支持。[1]
Tiens Pharmaceutical, a leading health supplement company, has quietly deployed significant capital into major artificial intelligence ventures through investment funds and personal networks. Beginning in April 2026, the company committed approximately 450 million yuan to participate in funding rounds for prominent AI firms including DeepSeek, Moonshot AI, and StepFun, while also building positions in chip enterprises.[1]
The company secured a 0.04% stake in DeepSeek by investing 130 million yuan through an indirect ownership structure via Lisi Capital, where it holds an LP stake.[1] Additionally, Tiens Pharmaceutical invested a combined 15 million U.S. dollars in Moonshot AI's Series D round, acquiring a 0.12% shareholding through a family connection—founder Liang Yunchao's mother-in-law, Sun Jinyu, holds equity in the company and facilitated the investment channel.[1] DeepSeek's valuation in this round ranged between 325 billion and 350.9 billion yuan.[1]
The company's aggressive AI investment strategy has been enabled by its strong financial position. As of the end of 2025, Tiens Pharmaceutical held 2.449 billion yuan in cash and equivalents while maintaining a low asset-to-liability ratio of just 19.95%, providing ample resources to pursue opportunities in the booming AI sector.[1]
